Trial Profile
A randomized, single-dose, crossover study to assess relative bioavailability of somatropin delivered with a needle-free device compared with traditional SC injection and Coadministered With the Growth Hormone Inhibitor Octreotide Acetate.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 May 2018
Price :
$35
*
At a glance
- Drugs Somatropin (Primary)
- Indications Short stature; Somatotropin deficiency
- Focus Pharmacokinetics
- 02 May 2018 New trial record
- 23 Apr 2018 Results published in the Clinical Therapeutics